Association of tumor perivascular desmin expression with survival in patients with sunitinib-treated renal carcinoma.

被引：0
|
作者：
Bolling, Magnus Frodin
Sandstrom, Per
Mezheyeuski, Artur
Egevad, Lars
Ostman, Arne
机构：
[1] Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden
[2] Karolinska Univ Hosp, Dept Oncol Pathol, Stockholm, Sweden
[3] Karolinska Inst, Stockholm, Sweden
[4] Karolinska Inst, Stockholm, Sweden
[5] Belarusian State Med Univ, Dept Pathol, Minsk, BELARUS
[6] Belarusian State Med Univ, Dept Pathol, Stockholm, Sweden
[7] Karolinska Univ Hosp, Dept Pathol, Stockholm, Sweden
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
11097
引用
收藏
页数：1
相关论文
共 50 条
  • [31] POLYMORPHISMS IN VEGFA, VEGFR1,-2 AND-3 ARE ASSOCIATED WITH RESPONSE AND OUTCOME OF SUNITINIB-TREATED METASTATIC RENAL CELL CARCINOMA PATIENTS
    Dornbusch, Juana
    Walter, Martina
    Gottschalk, Andrea
    Obaje, Alice
    Junker, Kerstin
    Ohlmann, Carsten-Henning
    Meinhardt, Matthias
    Zacharis, Aristeidis
    Zastrow, Stefan
    Grimm, Marc-Oliver
    Klug, Stefanie J.
    Fuessel, Susanne
    Wirth, Manfred P.
    JOURNAL OF UROLOGY, 2015, 193 (04): : E762 - E762
  • [32] Tumor lysis syndrome in a patient with a renal carcinoma treated with sunitinib.
    Rodriguez-Reimundes, Ezequiel
    Perazzo, Florencia
    Vilches, Antonio R.
    MEDICINA-BUENOS AIRES, 2011, 71 (02) : 158 - 160
  • [33] Sunitinib inducing tumor lysis syndrome in a patient treated for renal carcinoma
    Michels, Judith
    Lassau, Nathalie
    Gross-Goupil, Marine
    Massard, Christophe
    Mejean, Arnaud
    Escudier, Bernard
    INVESTIGATIONAL NEW DRUGS, 2010, 28 (05) : 690 - 693
  • [34] Association between clonal hematopoiesis and survival after nephrectomy in patients with renal cell carcinoma.
    Khandwala, Yash
    Ruthen, Neil
    Kotecha, Ritesh R.
    Russo, Paul
    Coleman, Jonathan
    Reznik, Eduard
    Hakimi, A. Ari
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
  • [35] Sunitinib inducing tumor lysis syndrome in a patient treated for renal carcinoma
    Judith Michels
    Nathalie Lassau
    Marine Gross-Goupil
    Christophe Massard
    Arnaud Mejean
    Bernard Escudier
    Investigational New Drugs, 2010, 28 : 690 - 693
  • [36] Association between tumor burden and response to immunotherapy in patients with metastatic renal cell carcinoma.
    Yasin, Hesham Abdallah
    Chen, Yu-Wei
    Tucker, Matthew D.
    Beckermann, Katy
    Schaffer, Kerry
    Davis, Nancy B.
    McAlister, Renee
    Wallace, Deborah
    Kaiser, Elizabeth
    Rini, Brian I.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [37] Olecranon bursitis in patients treated with sunitinib for renal cell carcinoma
    Thomas Gregory
    Olivier Mir
    Jacques Medioni
    Bernard Augereau
    Stéphane Oudard
    Medical Oncology, 2010, 27 : 446 - 448
  • [38] Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib
    Rini, Brian I.
    Tamaskar, Ila
    Shaheen, Phillip
    Salas, Renee
    Garcia, Jorge
    Wood, Laura
    Reddy, Sethu
    Dreicer, Robert
    Bukowski, Ronald M.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2007, 99 (01): : 81 - 83
  • [39] Olecranon bursitis in patients treated with sunitinib for renal cell carcinoma
    Gregory, Thomas
    Mir, Olivier
    Medioni, Jacques
    Augereau, Bernard
    Oudard, Stephane
    MEDICAL ONCOLOGY, 2010, 27 (02) : 446 - 448
  • [40] A MODEL RELATING OVERALL SURVIVAL RELATED TO TUMOR GROWTH INHIBITION IN RENAL CELL CARCINOMA PATIENTS TREATED WITH SUNITINIB, AXITINIB OR TEMSIROLIMUS.
    Mercier, F.
    Claret, L.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 : S68 - S68
12345